I reported previously (see here) on Israel’s BioCanCell which is developing treatments for bladder, ovarian and pancreatic cancers. It has changed its name to Anchiano and plans to list on NASDAQ. In December, Anchiano began a pivotal trial of its BC-819 H19 gene therapy for bladder cancer.

https://www.anchiano.com/anchiano-announces-initiation-of-its-codex-study-of-inodiftagene-vixteplasmid-in-patients-with-nmibc/

https://www.calcalistech.com/ctech/articles/0,7340,L-3753914,00.html